Clinical Trials on Stellate Ganglion Block in Japan

Total 87 results

Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients

Parkinson's Disease

Japan
AbbVie

Completed

An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications

Advanced Parkinson's Disease

Japan, Korea, Republic of, Taiwan
GlaxoSmithKline

Completed

Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease

Parkinson Disease

Japan
Biogen

Terminated

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

Parkinson's Disease

Japan
Takeda

Completed

A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

Parkinson's Disease

Japan
Boehringer Ingelheim

Completed

A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment Period

Parkinson Disease

Japan
H. Lundbeck A/S

Active, not recruiting

A Study of Lu AF82422 in Participants With Multiple System Atrophy (AMULET)

Multiple System Atrophy

United States, Japan
Novartis

Completed

Evaluation of the Efficacy and Safety of AFQ056 in Reducing Moderate to Severe L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Parkinson Disease | Dyskinesias

Italy, Spain, France, Germany, Finland, Japan, Australia, Canada
Takeda

Completed

A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients

Parkinson's Disease

Japan
Takeda

Completed

A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants

Parkinson's Disease

Japan
Alexion Pharmaceuticals, Inc.

Terminated

Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease

Wilson Disease

Spain, Korea, Republic of, France, Germany, Japan, Australia, Poland, United Kingdom
Takeda

Completed

A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

Parkinson's Disease

Japan
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany
Kliniken Beelitz GmbH
Hannover Medical School; University Hospital Muenster; Medical University Innsbruck and other collaborators

Recruiting

Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies (FEEMSA)

Parkinson Disease | Multiple System Atrophy | Progressive Supranuclear Palsy

Germany, Austria, Israel, Italy, Poland, Spain, Japan, Korea, Republic of
Genzyme, a Sanofi Company

Terminated

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation (MOVES-PD)

Parkinson's Disease

United States, Austria, Canada, France, Germany, Greece, Israel, Italy, Japan, Norway, Portugal, Singapore, Spain, Sweden, Taiwan, United Kingdom
Boehringer Ingelheim

Completed

Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa

Parkinson Disease

Japan
Eisai Co., Ltd.

Completed

A Double-blind Study of E2020 (Donepezil Hydrochloride) in Patients With Dementia With Lewy Bodies (DLB) (Study E2020-J081-431)

Dementia With Lewy Bodies (DLB)

Japan
AbbVie

Active, not recruiting

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, United Kingdom, Sweden
Boehringer Ingelheim

Completed

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

Parkinson Disease

United States, Austria, Czech Republic, Finland, France, Germany, Hungary, India, Japan, Malaysia, Netherlands, Russian Federation, Slovakia, Taiwan, Ukraine
Boehringer Ingelheim

Completed

Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)

Parkinson Disease

United States, Austria, Finland, France, Germany, Italy, Japan, Spain, Sweden, United Kingdom
AbbVie

Terminated

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy (PSP)

United States, Australia, Canada, Italy, Japan
Boehringer Ingelheim

Completed

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Early Parkinson Disease (Early PD)

United States, Argentina, Austria, Czech Republic, Finland, Germany, Hungary, India, Japan, Malaysia, Russian Federation, Slovakia, Taiwan, Ukraine
AbbVie

Completed

A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)

Parkinson's Disease (PD)

United States, Australia, Belgium, Canada, Denmark, Germany, Italy, Japan, Netherlands, Russian Federation, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's Disease

Parkinson Disease

Japan
Biogen
Denali Therapeutics Inc.

Recruiting

A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA)

Parkinson Disease

United States, Netherlands, Italy, Spain, Israel, Canada, China, Germany, France, Austria, United Kingdom, Poland, Japan
Boehringer Ingelheim

Completed

Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole

Parkinson Disease

Japan
Boehringer Ingelheim

Completed

Special Survey on PD Patients With Renal Dysfunction

Parkinson Disease

Japan
AbbVie

Terminated

A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States, Australia, Canada, France, Germany, Italy, Japan, Spain
AbbVie

Active, not recruiting

Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease

Parkinson's Disease

Japan
Eisai Inc.

Completed

Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies

Dementia With Lewy Bodies

United States, Spain, France, Germany, Italy, Japan, United Kingdom
Boehringer Ingelheim

Completed

Survey on PD Patients With Depressive Symptoms

Parkinson Disease

Japan
Biogen

Terminated

Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PASSPORT)

Supranuclear Palsy, Progressive

United States, France, Italy, Korea, Republic of, Russian Federation, Spain, United Kingdom, Austria, Canada, Germany, Japan, Australia, Greece
Eisai Co., Ltd.

Completed

A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase

Dementia With Lewy Bodies (DLB)

Japan
Alexion Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

Wilson Disease

United States, Spain, Taiwan, France, Czechia, Hungary, Turkey, United Kingdom, Austria, Germany, Israel, Serbia, Australia, Japan, Denmark, Korea, Republic of, New Zealand, Canada, Russian Federation, Poland, Singapore, Hong Kong
Takeda
AstraZeneca

Recruiting

A Study of TAK-341 in Treatment of Multiple System Atrophy

Multiple System Atrophy

Spain, Germany, United States, Italy, United Kingdom, Austria, Denmark, France, Japan, Portugal
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Participants With Manifest Huntington's Disease

Huntingtons Disease

United States, United Kingdom, Australia, Canada, Japan, Poland, Netherlands, Germany, Russian Federation, France, Spain, Argentina, New Zealand, Austria, Denmark, Italy, Switzerland, Chile

Clinical Trials on Stellate Ganglion Block in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations